altretamine has been researched along with Local Neoplasm Recurrence in 27 studies
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later." | 9.08 | Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997) |
| "A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later." | 5.08 | Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997) |
| "A prospective randomized study was conducted in women with suboptimal (greater than or equal to 3 cm residual) Stage III, Stage IV, and recurrent ovarian adenocarcinoma to determine if combination chemotherapy is more effective than melphalan alone in achieving remission and improving survival." | 5.05 | A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. ( Blessing, JA; Buchsbaum, HJ; Homesley, HD; Leone, L; Miller, A; Morrow, CP; Omura, GA, 1983) |
| "The standard treatment for ovarian cancer is cytoreductive surgery followed by platinum-based combination chemotherapy." | 2.39 | [Chemotherapy for recurrent ovarian cancer]. ( Chang, C; Imamura, K; Nishimura, H, 1996) |
| "Altretamine has reported efficacy in the treatment of recurrent ovarian cancer following platinum-based therapy." | 1.32 | Oral altretamine used as salvage therapy in recurrent ovarian cancer. ( Berman, ML; Chan, JK; Loizzi, V; Manetta, A, 2004) |
| "Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug." | 1.28 | Hexamethylmelamine as a single second-line agent in ovarian cancer. ( Larson, JE; Lyter, JA; MacNeill, C; Manetta, A; Podczaski, ES; Scheffler, B; Schein, P, 1990) |
| "Eighteen women with bulky ovarian cancer at the start of chemotherapy were brought to second laparotomy after 6 months of combination chemotherapy in an effort to resect previously unresectable tumor masses." | 1.27 | "Second-effort" surgical resection for bulky ovarian cancer. ( Calanog, A; Camacho, F; Greenwald, E; Kaplan, BH; Moukhtar, M; Seltzer, V; Vogl, SE, 1984) |
| "Eleven women with advanced ovarian cancer treated postoperatively with combination chemotherapy (cytoxan, hexamethylmelamine, Adriamycin, and cis-platinum) had disease-free intervals of 5 to 46 months (mean: 22 months) and subsequently developed recurrent carcinoma." | 1.27 | Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. ( Kaplan, B; Seltzer, V; Vogl, S, 1985) |
| "Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV)." | 1.26 | Epithelial carcinoma of the ovary: current strategies. ( Kapp, DS; Katz, ME; Luikart, S; Schwartz, PE, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (59.26) | 18.7374 |
| 1990's | 9 (33.33) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, JK | 1 |
| Loizzi, V | 1 |
| Manetta, A | 4 |
| Berman, ML | 1 |
| Markman, M | 2 |
| Liu, PY | 1 |
| Rothenberg, ML | 1 |
| Monk, BJ | 1 |
| Brady, M | 1 |
| Alberts, DS | 2 |
| Surwit, EA | 1 |
| Crisp, W | 1 |
| Jackson, RA | 1 |
| Grozea, PN | 1 |
| Leigh, S | 1 |
| Brower, MS | 1 |
| Coleman, M | 1 |
| Pasmantier, MW | 1 |
| Silver, RT | 1 |
| Mamaril, AP | 1 |
| Quiguyan, CC | 1 |
| Omura, GA | 1 |
| Morrow, CP | 1 |
| Blessing, JA | 3 |
| Miller, A | 1 |
| Buchsbaum, HJ | 1 |
| Homesley, HD | 1 |
| Leone, L | 1 |
| Hainsworth, JD | 2 |
| Malcolm, A | 1 |
| Johnson, DH | 1 |
| Burnett, LS | 2 |
| Jones, HW | 2 |
| Greco, FA | 2 |
| Vogl, SE | 1 |
| Seltzer, V | 2 |
| Calanog, A | 1 |
| Moukhtar, M | 1 |
| Camacho, F | 1 |
| Kaplan, BH | 1 |
| Greenwald, E | 1 |
| Freedman, RS | 1 |
| Herson, J | 1 |
| Wharton, JT | 1 |
| Rutledge, FN | 1 |
| Katz, ME | 1 |
| Schwartz, PE | 1 |
| Kapp, DS | 1 |
| Luikart, S | 1 |
| Tempero, MA | 1 |
| Kessinger, A | 1 |
| Thigpen, JT | 2 |
| Vance, RB | 1 |
| Khansur, T | 1 |
| Moore, DH | 2 |
| Valea, F | 1 |
| Crumpler, LS | 2 |
| Fowler, WC | 2 |
| Rose, PG | 1 |
| Arseneau, J | 1 |
| Nishimura, H | 1 |
| Imamura, K | 1 |
| Chang, C | 1 |
| Rustin, GJ | 1 |
| Nelstrop, AE | 1 |
| Crawford, M | 1 |
| Ledermann, J | 1 |
| Lambert, HE | 1 |
| Coleman, R | 1 |
| Johnson, J | 1 |
| Evans, H | 1 |
| Brown, S | 1 |
| Oster, W | 1 |
| Tewari, K | 1 |
| Podczaski, ES | 2 |
| ten Bokkel Huinink, WW | 1 |
| Dalesio, O | 1 |
| Rodenhuis, S | 1 |
| Dubbelman, R | 1 |
| Hilton, A | 1 |
| Franklin, H | 1 |
| Koier, I | 1 |
| van Tinteren, H | 1 |
| van der Burg, ME | 1 |
| van Oosterom, AT | 1 |
| Jones, CP | 1 |
| MacNeill, C | 1 |
| Lyter, JA | 1 |
| Scheffler, B | 1 |
| Larson, JE | 1 |
| Schein, P | 1 |
| Abeloff, MD | 1 |
| Berkman, AW | 1 |
| Waterfield, WC | 1 |
| Remick, SC | 1 |
| Neville, AJ | 1 |
| Willson, JK | 1 |
| Louie, KG | 1 |
| Ozols, RF | 1 |
| Myers, CE | 1 |
| Ostchega, Y | 1 |
| Jenkins, J | 1 |
| Howser, D | 1 |
| Young, RC | 1 |
| Grubb, BP | 1 |
| Thant, M | 1 |
| Grosh, WW | 1 |
| Wolff, SN | 1 |
| Ball, H | 1 |
| Hanjani, P | 1 |
| Homesley, H | 1 |
| Posada, JG | 1 |
| Marantz, AB | 1 |
| Yeung, KY | 1 |
| Smith, FP | 1 |
| Delgado, G | 1 |
| Edwards, BK | 1 |
| Schein, PS | 1 |
| Vogl, S | 1 |
| Kaplan, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy[NCT00003120] | Phase 3 | 308 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for altretamine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Second-line chemotherapy for recurrent carcinoma of the ovary.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Hum | 1993 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Adenocarcinoma, Clear Cell; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 1996 |
Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating; Antineoplastic Combi | 1997 |
9 trials available for altretamine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; D | 1983 |
Single-agent chemotherapy for recurrent carcinoma of the cervix.
Topics: Altretamine; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Doxorubicin; | 1980 |
Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Altretamine; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female; Humans; Neoplasm R | 1996 |
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating | 1997 |
Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating; Antineoplastic Combi | 1997 |
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 1992 |
Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Altretamine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 1991 |
Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cis | 1987 |
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1986 |
16 other studies available for altretamine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Oral altretamine used as salvage therapy in recurrent ovarian cancer.
Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Agents, Alkylating; Female; Humans; Middle A | 2004 |
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progressi | 2006 |
Multiagent chemotherapy in relapsing ovarian cancer.
Topics: Altretamine; Bleomycin; Cisplatin; Clone Cells; Drug Therapy, Combination; Female; Humans; Neoplasm | 1983 |
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Combined Chemotherapy Protocol | 1984 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
"Second-effort" surgical resection for bulky ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modali | 1984 |
Epithelial carcinoma of the ovary: current strategies.
Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Doxorubicin; Drug Thera | 1981 |
Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma.
Topics: Adenocarcinoma, Papillary; Aged; Altretamine; Drug Therapy, Combination; Female; Humans; Melphalan; | 1982 |
Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Carcinoma; Female; Humans; Middle Aged; Neoplasm Recurr | 1993 |
Hexamethylmelamine as a single second-line agent in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local | 1990 |
Intensive alternating chemotherapy regimen in small cell carcinoma of the lung.
Topics: Actuarial Analysis; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D | 1985 |
Acute myelocytic leukemia in a patient treated with hexamethylmelamine.
Topics: Aged; Altretamine; Female; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Ovarian Neo | 1986 |
Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl | 1988 |
Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm | 1988 |
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modali | 1985 |